MicroStrategy® Incorporated (NASDAQ: MSTR), a leading worldwide provider of business intelligence software, today announced that ImpactRx®, a leading provider of market and sales force effectiveness insight to the pharmaceutical industry, has selected MicroStrategy for reporting and analysis of ph
McLean, Va., (August 09, 2005) –
MicroStrategy® Incorporated (NASDAQ: MSTR), a leading worldwide provider of business intelligence software, today announced that ImpactRx®, a leading provider of market and sales force effectiveness insight to the pharmaceutical industry, has selected MicroStrategy for reporting and analysis of pharmaceutical data for top drug companies and Wall Street firms. ImpactRx, Inc. is a pioneering force in assessing the impact of pharmaceutical promotion through the use of state of the art techniques such as longitudinal physician networks and handheld data capture devices to improve the accuracy, reliability, and speed of insight for improved promotional decision making.
ImpactRx Account Service Analysts use MicroStrategy as a reporting and analysis tool to enhance the quality of data they provide to customers. The analysts tap into the data warehouse using MicroStrategy to ensure quality control of data and to improve turnaround time on special information requests. ImpactRx selected MicroStrategy for its ability to handle large, complex analytical models and its product suite integration.
“We evaluated other business intelligence products, including Business Objects and Cognos, and we chose MicroStrategy because of its advanced technology, integrated platform, and data scalability,” said ImpactRx MIS Director, Michael Barrett. “ImpactRx delivers timely, accurate, and sensitive market intelligence data to the pharmaceutical industry and MicroStrategy enables us to work more efficiently and to promptly respond to customers’ complex data requests with improved data quality and consistency.”
“We are pleased that ImpactRx selected MicroStrategy’s integrated platform and powerful reporting capabilities to support their customers’ pharmaceutical data requirements,” said Sanju Bansal, MicroStrategy’s COO. “Our customer footprint in the pharmaceutical industry has continued to expand. Nine of the top ten global pharmaceutical companies use MicroStrategy.”
About ImpactRx
Founded in October 2000, ImpactRx’s physician network is the source of an unprecedented intelligence capability for tracking the promotional initiatives of the pharmaceutical industry and determining their impact on physician behavior. Based in Mount Laurel, New Jersey, ImpactRx is a private company with investment financing provided by Mediphase Venture Partners (http://www.mediphaseventure.com), Oxford Bioscience Partners (http://www.oxbio.com), Merck Capital Ventures (http://www.merckcapitalventures.com) and 3i (http://www.3i.com). For more information about ImpactRx, please visit http://www.impactrx.com.
About MicroStrategy
Founded in 1989, MicroStrategy is a global leader in business intelligence (BI) technology. MicroStrategy provides integrated reporting, analysis, and monitoring software that helps leading organizations worldwide make better business decisions every day. Companies choose MicroStrategy for its advanced technical capabilities, sophisticated analytics, and superior data and user scalability. More information about MicroStrategy (NASDAQ: MSTR) is available at www.microstrategy.com.
This press release may include statements that may constitute “forward-looking statements,” including its estimates of future business prospects or financial results and statements containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks that could cause MicroStrategy’s actual results to differ materially from the forward-looking statements. Factors that could contribute to such differences include: the ability of MicroStrategy to implement and achieve widespread customer acceptance of its software on a timely basis; delays in MicroStrategy’s ability to develop or ship new products; market acceptance of new products; competitive factors; currency fluctuations; and other risks detailed in MicroStrategy’s periodic reports filed with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
MicroStrategy, MicroStrategy Business Intelligence Platform are either trademarks or registered trademarks of MicroStrategy Incorporated in the United States and certain other countries. Other product and company names mentioned herein may be the trademarks of their respective owners.
Source: MicroStrategy